FLT3 and acute myeloid leukemia: Here, we report the results of the RADIUS trial investigating whether the addition of midostaurin to standard-of-care (SOC) treatment post-alloHSCT improves RFS over SOC alone in patients with FLT3-ITD-positive AML.